Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
23
INDP Quote, Financials, Valuation and Earnings
Last price:
$1.80
Seasonality move
:
-3.86%
Day range:
$1.79 - $1.90
52-week range:
$1.52 - $47.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.22x
Volume:
49.3K
Avg. volume:
1.2M
1-year change:
-91.98%
Market cap:
$1M
Revenue:
--
EPS (TTM):
-$22.83
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INDP
Indaptus Therapeutics, Inc.
|
-- | -$0.41 | -- | -12.77% | $10.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
APLT
Applied Therapeutics, Inc.
|
-- | -$0.13 | 104.92% | -20.37% | $0.25 |
|
CTXR
Citius Pharmaceuticals, Inc.
|
$3.5M | -$0.24 | -- | -84.9% | $6.00 |
|
DRMA
Dermata Therapeutics, Inc.
|
-- | -- | -- | -- | $10.00 |
|
DVAX
Dynavax Technologies Corp.
|
$80.3M | $0.08 | 11.43% | 73.54% | $20.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INDP
Indaptus Therapeutics, Inc.
|
$1.80 | $10.00 | $1M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.22 | $31.21 | $3.9B | 14.94x | $0.00 | 0% | 3.73x |
|
APLT
Applied Therapeutics, Inc.
|
$0.10 | $0.25 | $14.9M | -- | $0.00 | 0% | 14.67x |
|
CTXR
Citius Pharmaceuticals, Inc.
|
$0.75 | $6.00 | $15.7M | -- | $0.00 | 0% | -- |
|
DRMA
Dermata Therapeutics, Inc.
|
$1.83 | $10.00 | $1.9M | -- | $0.00 | 0% | -- |
|
DVAX
Dynavax Technologies Corp.
|
$15.50 | $20.50 | $1.8B | 54.00x | $0.00 | 0% | 6.48x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INDP
Indaptus Therapeutics, Inc.
|
0.19% | 0.377 | 0.53% | 2.61x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
APLT
Applied Therapeutics, Inc.
|
128.93% | 3.082 | 2.86% | 0.36x |
|
CTXR
Citius Pharmaceuticals, Inc.
|
2.61% | 7.162 | 5.6% | 0.09x |
|
DRMA
Dermata Therapeutics, Inc.
|
-- | -0.561 | -- | 4.20x |
|
DVAX
Dynavax Technologies Corp.
|
35.13% | -0.783 | 24.82% | 6.74x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INDP
Indaptus Therapeutics, Inc.
|
-- | -$2.6M | -375.21% | -537.86% | -- | -$3.1M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
APLT
Applied Therapeutics, Inc.
|
$889K | -$16.8M | -70.3% | -77.88% | -1675.8% | -$18.4M |
|
CTXR
Citius Pharmaceuticals, Inc.
|
-$62K | -$8.4M | -55.69% | -56.5% | -- | -$17.6M |
|
DRMA
Dermata Therapeutics, Inc.
|
-- | -$1.8M | -190.86% | -190.86% | -- | -$1.8M |
|
DVAX
Dynavax Technologies Corp.
|
$80.5M | $21.3M | -5.15% | -7.65% | 22.42% | $32.6M |
Indaptus Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns INDP or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Indaptus Therapeutics, Inc.'s net margin of 25.76%. Indaptus Therapeutics, Inc.'s return on equity of -537.86% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital INDPIndaptus Therapeutics, Inc.-- -$2.98 $4.6M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About INDP or ACAD?
Indaptus Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 455.56%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 34.41%. Given that Indaptus Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Indaptus Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INDPIndaptus Therapeutics, Inc.0 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is INDP or ACAD More Risky?
Indaptus Therapeutics, Inc. has a beta of 0.991, which suggesting that the stock is 0.95% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock INDP or ACAD?
Indaptus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indaptus Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INDP or ACAD?
Indaptus Therapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Indaptus Therapeutics, Inc.'s net income of -$3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Indaptus Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indaptus Therapeutics, Inc. is -- versus 3.73x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INDPIndaptus Therapeutics, Inc.-- -- -- -$3M ACADACADIA Pharmaceuticals, Inc.3.73x 14.94x $278.6M $71.8M
-
Which has Higher Returns INDP or APLT?
Applied Therapeutics, Inc. has a net margin of -- compared to Indaptus Therapeutics, Inc.'s net margin of -1899%. Indaptus Therapeutics, Inc.'s return on equity of -537.86% beat Applied Therapeutics, Inc.'s return on equity of -77.88%.
Company Gross Margin Earnings Per Share Invested Capital INDPIndaptus Therapeutics, Inc.-- -$2.98 $4.6M APLTApplied Therapeutics, Inc.88.9% -$0.13 $1.9M -
What do Analysts Say About INDP or APLT?
Indaptus Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 455.56%. On the other hand Applied Therapeutics, Inc. has an analysts' consensus of $0.25 which suggests that it could grow by 142.72%. Given that Indaptus Therapeutics, Inc. has higher upside potential than Applied Therapeutics, Inc., analysts believe Indaptus Therapeutics, Inc. is more attractive than Applied Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INDPIndaptus Therapeutics, Inc.0 0 0 APLTApplied Therapeutics, Inc.0 1 0 -
Is INDP or APLT More Risky?
Indaptus Therapeutics, Inc. has a beta of 0.991, which suggesting that the stock is 0.95% less volatile than S&P 500. In comparison Applied Therapeutics, Inc. has a beta of 2.077, suggesting its more volatile than the S&P 500 by 107.663%.
-
Which is a Better Dividend Stock INDP or APLT?
Indaptus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indaptus Therapeutics, Inc. pays -- of its earnings as a dividend. Applied Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INDP or APLT?
Indaptus Therapeutics, Inc. quarterly revenues are --, which are smaller than Applied Therapeutics, Inc. quarterly revenues of $1M. Indaptus Therapeutics, Inc.'s net income of -$3M is higher than Applied Therapeutics, Inc.'s net income of -$19M. Notably, Indaptus Therapeutics, Inc.'s price-to-earnings ratio is -- while Applied Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indaptus Therapeutics, Inc. is -- versus 14.67x for Applied Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INDPIndaptus Therapeutics, Inc.-- -- -- -$3M APLTApplied Therapeutics, Inc.14.67x -- $1M -$19M
-
Which has Higher Returns INDP or CTXR?
Citius Pharmaceuticals, Inc. has a net margin of -- compared to Indaptus Therapeutics, Inc.'s net margin of --. Indaptus Therapeutics, Inc.'s return on equity of -537.86% beat Citius Pharmaceuticals, Inc.'s return on equity of -56.5%.
Company Gross Margin Earnings Per Share Invested Capital INDPIndaptus Therapeutics, Inc.-- -$2.98 $4.6M CTXRCitius Pharmaceuticals, Inc.-- -$0.44 $79.3M -
What do Analysts Say About INDP or CTXR?
Indaptus Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 455.56%. On the other hand Citius Pharmaceuticals, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 695.02%. Given that Citius Pharmaceuticals, Inc. has higher upside potential than Indaptus Therapeutics, Inc., analysts believe Citius Pharmaceuticals, Inc. is more attractive than Indaptus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INDPIndaptus Therapeutics, Inc.0 0 0 CTXRCitius Pharmaceuticals, Inc.1 1 0 -
Is INDP or CTXR More Risky?
Indaptus Therapeutics, Inc. has a beta of 0.991, which suggesting that the stock is 0.95% less volatile than S&P 500. In comparison Citius Pharmaceuticals, Inc. has a beta of 1.613, suggesting its more volatile than the S&P 500 by 61.314%.
-
Which is a Better Dividend Stock INDP or CTXR?
Indaptus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indaptus Therapeutics, Inc. pays -- of its earnings as a dividend. Citius Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INDP or CTXR?
Indaptus Therapeutics, Inc. quarterly revenues are --, which are smaller than Citius Pharmaceuticals, Inc. quarterly revenues of --. Indaptus Therapeutics, Inc.'s net income of -$3M is higher than Citius Pharmaceuticals, Inc.'s net income of -$8.7M. Notably, Indaptus Therapeutics, Inc.'s price-to-earnings ratio is -- while Citius Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indaptus Therapeutics, Inc. is -- versus -- for Citius Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INDPIndaptus Therapeutics, Inc.-- -- -- -$3M CTXRCitius Pharmaceuticals, Inc.-- -- -- -$8.7M
-
Which has Higher Returns INDP or DRMA?
Dermata Therapeutics, Inc. has a net margin of -- compared to Indaptus Therapeutics, Inc.'s net margin of --. Indaptus Therapeutics, Inc.'s return on equity of -537.86% beat Dermata Therapeutics, Inc.'s return on equity of -190.86%.
Company Gross Margin Earnings Per Share Invested Capital INDPIndaptus Therapeutics, Inc.-- -$2.98 $4.6M DRMADermata Therapeutics, Inc.-- -$1.65 $4M -
What do Analysts Say About INDP or DRMA?
Indaptus Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 455.56%. On the other hand Dermata Therapeutics, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 446.45%. Given that Indaptus Therapeutics, Inc. has higher upside potential than Dermata Therapeutics, Inc., analysts believe Indaptus Therapeutics, Inc. is more attractive than Dermata Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INDPIndaptus Therapeutics, Inc.0 0 0 DRMADermata Therapeutics, Inc.0 0 0 -
Is INDP or DRMA More Risky?
Indaptus Therapeutics, Inc. has a beta of 0.991, which suggesting that the stock is 0.95% less volatile than S&P 500. In comparison Dermata Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock INDP or DRMA?
Indaptus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dermata Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indaptus Therapeutics, Inc. pays -- of its earnings as a dividend. Dermata Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INDP or DRMA?
Indaptus Therapeutics, Inc. quarterly revenues are --, which are smaller than Dermata Therapeutics, Inc. quarterly revenues of --. Indaptus Therapeutics, Inc.'s net income of -$3M is lower than Dermata Therapeutics, Inc.'s net income of -$1.7M. Notably, Indaptus Therapeutics, Inc.'s price-to-earnings ratio is -- while Dermata Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indaptus Therapeutics, Inc. is -- versus -- for Dermata Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INDPIndaptus Therapeutics, Inc.-- -- -- -$3M DRMADermata Therapeutics, Inc.-- -- -- -$1.7M
-
Which has Higher Returns INDP or DVAX?
Dynavax Technologies Corp. has a net margin of -- compared to Indaptus Therapeutics, Inc.'s net margin of 28.38%. Indaptus Therapeutics, Inc.'s return on equity of -537.86% beat Dynavax Technologies Corp.'s return on equity of -7.65%.
Company Gross Margin Earnings Per Share Invested Capital INDPIndaptus Therapeutics, Inc.-- -$2.98 $4.6M DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M -
What do Analysts Say About INDP or DVAX?
Indaptus Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 455.56%. On the other hand Dynavax Technologies Corp. has an analysts' consensus of $20.50 which suggests that it could grow by 41.94%. Given that Indaptus Therapeutics, Inc. has higher upside potential than Dynavax Technologies Corp., analysts believe Indaptus Therapeutics, Inc. is more attractive than Dynavax Technologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings INDPIndaptus Therapeutics, Inc.0 0 0 DVAXDynavax Technologies Corp.1 1 1 -
Is INDP or DVAX More Risky?
Indaptus Therapeutics, Inc. has a beta of 0.991, which suggesting that the stock is 0.95% less volatile than S&P 500. In comparison Dynavax Technologies Corp. has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.716%.
-
Which is a Better Dividend Stock INDP or DVAX?
Indaptus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dynavax Technologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indaptus Therapeutics, Inc. pays -- of its earnings as a dividend. Dynavax Technologies Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INDP or DVAX?
Indaptus Therapeutics, Inc. quarterly revenues are --, which are smaller than Dynavax Technologies Corp. quarterly revenues of $94.9M. Indaptus Therapeutics, Inc.'s net income of -$3M is lower than Dynavax Technologies Corp.'s net income of $26.9M. Notably, Indaptus Therapeutics, Inc.'s price-to-earnings ratio is -- while Dynavax Technologies Corp.'s PE ratio is 54.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indaptus Therapeutics, Inc. is -- versus 6.48x for Dynavax Technologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INDPIndaptus Therapeutics, Inc.-- -- -- -$3M DVAXDynavax Technologies Corp.6.48x 54.00x $94.9M $26.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 10
Bill Holdings, Inc. [BILL] is up 3.7% over the past day.
Buy
75
PRLB alert for Feb 9
Proto Labs, Inc. [PRLB] is down 2.16% over the past day.
Sell
30
MSTR alert for Feb 9
Strategy, Inc. [MSTR] is up 2.59% over the past day.
